Patients at risk of complications of Staphylococcus aureus bloodstream infection
- PMID: 19374580
- DOI: 10.1086/598187
Patients at risk of complications of Staphylococcus aureus bloodstream infection
Abstract
Staphylococcus aureus is one of the most common causative pathogens of bloodstream infections (BSIs). In approximately one-half of patients with S. aureus BSI, no portal of entry can be documented. This group of patients has a high risk of developing septic metastases. Similarly, patient populations at high risk of S. aureus BSI and BSI-associated complications include patients receiving hemodialysis, injection drug users, patients with diabetes, and patients with preexisting cardiac conditions or other comorbidities. One of the most severe complications of S. aureus BSI is infective endocarditis, and S. aureus is now the most common cause of infective endocarditis in the developed world. Patients with methicillin-resistant S. aureus BSI or infective endocarditis have higher rates of mortality, compared with patients with methicillin-susceptible S. aureus infection. Nasal carriage is the most important source of S. aureus BSI. Better eradication and control strategies, including nasal decolonization and more-active antibiotics, are needed to combat S. aureus BSIs.
Similar articles
-
A prospective multicenter study of Staphylococcus aureus bacteremia: incidence of endocarditis, risk factors for mortality, and clinical impact of methicillin resistance.Medicine (Baltimore). 2003 Sep;82(5):322-32. doi: 10.1097/01.md.0000091185.93122.40. Medicine (Baltimore). 2003. PMID: 14530781
-
Staphylococcus aureus bacteremia: epidemiology, pathophysiology, and management strategies.Clin Infect Dis. 2009 May 15;48 Suppl 4:S231-7. doi: 10.1086/598189. Clin Infect Dis. 2009. PMID: 19374578
-
Nasal carriage of meticillin resistant Staphylococcus aureus: the prevalence, patients at risk and the effect of elimination on outcomes among outclinic haemodialysis patients.Eur J Med Res. 2007 Jul 26;12(7):284-8. Eur J Med Res. 2007. PMID: 17933699 Clinical Trial.
-
Staphylococcus aureus bloodstream infections: definitions and treatment.Clin Infect Dis. 2009 May 15;48 Suppl 4:S254-9. doi: 10.1086/598186. Clin Infect Dis. 2009. PMID: 19374581 Review.
-
Future strategies for treating Staphylococcus aureus bloodstream infections.Clin Microbiol Infect. 2008 Mar;14 Suppl 2:26-34. doi: 10.1111/j.1469-0691.2008.01924.x. Clin Microbiol Infect. 2008. PMID: 18226087 Review.
Cited by
-
Strong Biofilm Formation and Low Cloxacillin Susceptibility in Biofilm-Growing CC398 Staphylococcus aureus Responsible for Bacteremia in French Intensive Care Units, 2021.Microorganisms. 2022 Sep 16;10(9):1857. doi: 10.3390/microorganisms10091857. Microorganisms. 2022. PMID: 36144459 Free PMC article.
-
Risk and prognosis of Staphylococcus aureus bacteremia among individuals with and without end-stage renal disease: a Danish, population-based cohort study.BMC Infect Dis. 2015 Jan 8;15:6. doi: 10.1186/s12879-014-0740-8. BMC Infect Dis. 2015. PMID: 25566857 Free PMC article.
-
Outcome of methicillin-sensitive Staphylococcus aureus (MSSA) bacteremia: impact of diabetes.Eur J Clin Microbiol Infect Dis. 2019 Dec;38(12):2215-2220. doi: 10.1007/s10096-019-03659-z. Epub 2019 Aug 5. Eur J Clin Microbiol Infect Dis. 2019. PMID: 31385146
-
Staphylococcus aureus Bacteremia Among Patients Receiving Maintenance Hemodialysis: Trends in Clinical Characteristics and Outcomes.Am J Kidney Dis. 2022 Mar;79(3):393-403.e1. doi: 10.1053/j.ajkd.2021.06.018. Epub 2021 Jul 23. Am J Kidney Dis. 2022. PMID: 34303771 Free PMC article.
-
Repurposed drugs block toxin-driven platelet clearance by the hepatic Ashwell-Morell receptor to clear Staphylococcus aureus bacteremia.Sci Transl Med. 2021 Mar 24;13(586):eabd6737. doi: 10.1126/scitranslmed.abd6737. Sci Transl Med. 2021. PMID: 33762439 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical